<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1229">
  <stage>Registered</stage>
  <submitdate>28/04/2006</submitdate>
  <approvaldate>2/05/2006</approvaldate>
  <actrnumber>ACTRN12606000152527</actrnumber>
  <trial_identification>
    <studytitle>Lifestyle and pharmacological regulation of lipoprotein metabolism in the metabolic syndrome</studytitle>
    <scientifictitle>Effect of weight loss and ezetimibe on high-density lipoprotein (HDL)-apolipoprotein (apo) A-I and HDL apoA-II transport in obese dyslipidaemic patients</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Obesity
</healthcondition>
    <healthcondition>Type 2 diabetic mellitus</healthcondition>
    <healthcondition>Dyslipidaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Weight loss plus Ezetimibe (12 week diet restricting weight reduction program followed with 4 week weight stabilizing period; ezetimibe, 10mg/day, is administrated in form of oral tablet for 16 weeks)</interventions>
    <comparator>Weight loss (12 week diet restricting weight reduction program followed with 4 week weight stabilizing period) </comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>High density lipoprotein (HDL)-apolipoprotein (apo) A-I and HDL-apoA-II production rates</outcome>
      <timepoint>Before and after 16 week intervention program</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>High density lipoprotein (HDL)-apolipoprotein (apo) A-I and HDL-apoA-II catabolic rates</outcome>
      <timepoint>Before and after 16 week intervention program</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Apo B production and catabolic rates</outcome>
      <timepoint>Before and after 16 week intervention program.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cholesterol absorption and synthesis</outcome>
      <timepoint>Before and after 16 week intervention program.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>BMI &lt;40kg/m2 will be recruited. PM will be defined by: no menstrual cycle for 1 year and FSH &gt;30U/L, or if the subject has had a hysterectomy or surgical sterilization.  The MetS will be defined by the new International Diabetes Federation   (IDF) criteria: central obesity (waist circumference &gt;80cm for women and &gt;94cm for men) plus triglycerides =1.7mmol/L, non-HDL-cholesterol &gt;3.4mmol/L and insulin resistance (HOMA &gt;2.2).Exclusion: Subjects with genetic hyperlipidemia, (eg FH), LDL-cholesterol &gt;6.5mmol/L, proteinuria, hypothyroidism, alcoholism (&gt;30g/day), creatinaemia (&gt;130Âµmol/L), hepatic dysfunction (AST or ALT &gt;3x ULN) and major systemic illness; pre-menopause women;  use of steroids or other agents that may influence lipid metabolism, cardiovascular event within past 6 months, use of hypocaloric diets, anaemia;  a history of intolerance to ezetimibe.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central allocation by a statistican not involved in the trial</concealment>
    <sequence>Computer generated</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>4/05/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Western Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>National Heart Foundation of Australia</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study hypothesis is that inhibition of cholesterol absorption complements the effects of weight loss on lipid and lipoprotein transport in obese subjects. Specifically , the study aims to elucidate the mechanisms of action of a new therapeutic regimen (weight loss plus ezetimibe) for regulating lipid and lipoprotein transport in these subjects.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>21/02/2006</ethicapprovaldate>
      <hrec> EC2006/070</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Dick C Chan</name>
      <address>School of Medicine and Pharmacology
University of Western Australia
Level 4 MRF Building
Royal Perth Hospital
50 Murray Street Perth WA6000</address>
      <phone>61-8-92240268</phone>
      <fax />
      <email>dick.chan@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof Gerald F Watts</name>
      <address>School of Medicine and Pharmacology
University of Western Australia
Level 4, MRF Building
Royal Perth Hospital
50 Murray Street, Perth WA6000</address>
      <phone>61-8-92240251</phone>
      <fax />
      <email>gfwatts@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>